Background/Aims: Previous preclinical and clinical studies have reported a positive correlation between the expression of the C-C chemokine receptor 7 (CCR7) and the incidence of lymph node metastasis in breast cancer. However, the prognostic relevance of CCR7 expression in breast cancer remains contradictory till now. The aim of this study is to assess the correlation of the CCR7 expression with other clinicopathological features and prognosis in breast cancer. Methods: The CCR7 gene amplification and mRNA expression levels from approximately 3,000 patients were retrieved from human breast cancer databases and analyzed. Furthermore, a total of 188 primary triple negative breast cancer patients were enrolled in this study (diagnosed since January 2009 to January 2013 from the Second Hospital of Dalian Medical University). The protein levels of CCR7 were examined by immunohistochemistry using paraffin-embedded tumor tissues. Results: The analysis of gene amplification and mRNA levels showed the expression of CCR7 in breast cancer correlated with better prognosis. When we compared the CCR7 expressions in different subtypes, the basal-like group showed the highest expression of CCR7 and exhibited a better prognosis. Consistently, Kaplan-Meier analysis of 188 triple negative breast cancer patients showed that the prognosis of patients with positive CCR7 expression was significantly better than those with negative expression (HR=0.642, p=0.0275). Additionally, we also observed a positive correlation between lymph node metastasis and the CCR7 expression (p=0.0096). Conclusions: Our results indicated that elevated CCR7 expression as a marker for increased lymph node metastasis, in addition to serve as an independent prognostic indicator for better overall survival in triple negative breast cancer patients.
High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer
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Introduction
Transcriptional profiling analyses have identified the five subtypes of breast cancer, including normal-like, luminal A, luminal B, HER2-positive, and basal-like breast cancer [1] . Among these subtypes, basal-like breast cancer is strongly associated with aggressive phenotypes and poor prognosis [2] . This subtype largely overlaps with the clinically defined 'triple-negative' breast cancer, which lacks ER, PR, and HER2 expressions. The absence of these molecules renders this subtype unsusceptible to routine targeted therapies such as Herceptin/Trastuzumab. Therefore, to gain more understanding on this subtype, we set out to investigate the expressions of other molecules of prognostic significance.
Several preclinical and clinical studies [3] [4] [5] [6] [7] [8] have reported positive correlations between the incidence of lymph node metastases and the expression levels of the C-C chemokine receptor 7 in breast cancer (Table 1) . C-C chemokine receptor 7 (CCR7), a G proteincoupled trans-membrane protein, can promote immune cell viability and induce immune cells homing to secondary lymphoid organs following cognate ligand binding like cytokines CCL19 and CCL21 [9, 10] . Whereas the exact roles of CCR7 in disease progression and in tumor metastasis to lymphoid tissues remain controversial so far.
Two clinical studies have been conducted to investigate the relationship between clinicopathological characteristics and the expression levels of CCR7, although the prognostic significance of CCR7 expression in breast cancer still remains contradictory ( Table 1) . The study by Liu et al [7] . reported that the CCR7 expression was correlated with lymph node metastases and a poor overall survival in breast cancers (p=0.044). However, another study by Cassier et al [8] . did not draw the same conclusion, which reported that the expression of CCR7 was not significantly associated with either RFS (p=0.34) or OS (p=0.153). In addition, we observed that an intriguing subset of breast cancer patients with lymph node metastases exhibited a relative long-term survival from our clinical work, which prompted us to investigate the correlation between lymph node metastasis and overall survival. In order to assess the correlations between the CCR7 expression and the clinicopathological features and overall survival, we analyzed the expressions of CCR7 using gene amplification and mRNA expression data from the breast cancer databases and examined the prognostic value of CCR7 expression. Subsequently, we inspected the expressions of CCR7 protein using immunohistochemistry in 188 triple negative breast cancer tissues. In this study, by combining the analyses of CCR7 expressions at the gene, mRNA, and protein levels, we endeavor to validate the correlations between the CCR7 expression and lymph node metastasis and the overall survival in triple negative breast cancers.
Materials and Methods

Samples and Clinicopathological Data
A total of 188 surgically resected breast cancer specimens and twelve normal breast tissues were collected from the Second Hospital of Dalian Medical University between January 2009 and January 2013. None of the patients had received radiotherapy or chemotherapy prior to surgery. The inclusion criteria for this study was as follows: 1) patho logical examination as ER-, PR-, and HER2-, 2) more than 15 lymph nodes were examined after surgery, 3) the tumor specimens were unbroken and dyed uniformly by the antibody, and 4) the availability of a complete medical record. The demographic and clinical data of each patient were obtained from the medical records. Telephone follow-ups were performed every 3 months since the date of surgery. Written informed consent was obtained from all participants included in this study and the experimental protocol was approved by the ethics committee at the Second Hospital of Dalian Medical University. This study did not contain any studies with human participants or animals performed by any of the authors.
Immunohistochemistry
The tumor tissue samples were fixed in 10% formalin (pH 7.0) before embedded in paraffin. The protein expression of CCR7 was measured following a two-step method. Rabbit anti-CCR7 polyclonal 
Assessment of immunohistochemistry staining
CCR7 positive staining was defined as samples displaying clear brown granules in the cytoplasm. The staining was assessed by two experienced pathologists independently, who were blinded to diagnosis and prognosis. The expres sion levels were evaluated by the proportion and intensity of positively stained cells. The staining intensity was as follows: 0, negative; 1, light yellow; 2, brownish-yellow; 3, brown. The proportion score was as follows: 0, none; 1, <25%; 2, 25%-50%; 3, >50%. Total score < 3 was treated as negative and a score ≥3 was considered as positive.
Statistical analysis
Statistical analyses were performed using Prism 6. In the dot plots, each dot indicated an individual sample, with results rep resenting median with interquartile ranges. Data of the cohorts were downloaded from cBioPortal (www.cbioportal.com). Two-tailed Student's t-test and analysis of variance (ANOVA) were carried out to compare between two groups and among three groups, respectively. Kaplan-Meier curve, logrank (Mantel-Cox) test, and the hazard ratio were analyzed using Prism 6 and the online analytical system (http://kmplot.com/analysis/index, http://xena.ucsc.edu/public-hubs/). P-value< 0.05 was considered statistically significant.
Results
The recurrent CCR7 gene amplification predicts a better prognosis
We analyzed the amplification of CCR7 gene in four breast cancer cohorts retrieved from the cBioPortal, including TCGA_2015, TCGA, TCGA_pub, and METABRIC. We observed that the amplification of CCR7 gene was recurrent, at approximately 4-6% (Fig. 1A) . We next assessed the prognostic significance of CCR7 amplification in the TCGA_Pub breast cancer cohort, with results suggesting that cases with amplifications showed a better prognosis than those without amplification (p=0.0435) (Fig. 1B) . To assess whether CCR7 mRNA expression levels can also predict prognosis, patients were divided into top 50% 'CCR7 high' and bottom 50% 'CCR7 low' groups based on the CCR7 mRNA levels and Kaplan-Meier curves of overall survival were plotted. The survival analysis showed a consistent conclusion that the high CCR7 expression survived longer with high expression of CCR7 till approximately 210 weeks (p=0.0207, p=0.0002531) (Fig. 1C) . Our findings indicate that the CCR7 overexpression at both gene and mRNA levels can predict a good prognosis in breast cancers.
CCR7 is overexpressed in triple negative breast cancer
We next analyzed the gene expression data across three independent cohorts with a total number of about 3, 000 patients, including TCGA 2012_nature, TCGA_provisional, and Brca_metabric. With respect to the various subtypes of breast cancer, we observed that the ER-positive subtype displayed low expression levels of CCR7, while the HER2-positive and basal-like subtypes showed relative high expression levels of CCR7, even more obviously in the basal-like subtype ( Fig. 2A) . These results indicate that CCR7 expression is elevated in breast cancers lacking the expression of ER, while the basal-like group showed the highest expression levels of CCR7 among breast cancer subtypes.
High expression levels of CCR7 predict good prognosis in triple negative breast cancer
To assess the prognostic significance of CCR7 expression in breast cancer, patients were divided into high expression and low expression groups based on the expression of CCR7 in HER2-positive breast cancer and basal-like breast cancer. By analyzing survival data, we draw similar conclusions from both subtypes that 'CCR7 high' group showed a better prognosis (p=0.0058, p=0.0199) (Fig. 2B) . Besides, using another web-based analysis tool (http://kmplot.com), we reached the same conclusion that 'CCR7 high' group had a significantly better prognosis in the basal-like subtype of breast cancer (p=0.029) (Fig. 2C) . Taken together, the results from our analyses show that the high expression of CCR7 was correlated with good prognosis in HER2 positive and basal-like breast cancers, with more significant association observed in the basal-like subtype.
Clinical relevance of CCR7 protein expression
Subsequently, we investigated whether the protein expression of CCR7 was associated with clinicopathological features in triple negative breast cancer. Therefore, we measured the CCR7 protein expressions in breast cancer tissues with immunohistochemistry (Fig. 3) , from which we observed CCR7 staining of the cytoplasm and nuclear membrane that was further confirmed by carrying out immunofluorescence experiments (Fig. 3) . Based on results from immunohistochemical analyses, no significant statistical association of CCR7 expression was observed with patient age, number of meta static axillary nodes, and histologic grade (Table 2) . However, the expression of CCR7 was significantly associated with the diameter of primary tumor (p=0.0409) and TNM staging (p=0.0001). Samples were divided into two groups with and without CCR7 gene amplifications.
(C) Kaplan-Meier curves of overall survival of breast cancer patients were analyzed by using Prism 6 (left), and the online analytical system (right) from http://xena.ucsc.edu/ public-hubs/.Samples were divided into two groups with high and low expression levels of CCR7. 
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Breast cancer
In this study, a total of 188 cases were followed up for 46 months after surgery. The median survival time was 32 months. Ninety-seven patients died during follow-up, and all causes of death were cancer related. We performed Coxregression analysis to evaluate clinical factors, which showed that TNM staging (P=0.0137, HR=0.6142) and CCR7 expression levels (p=0.0275, HR=0.6330) were significantly correlated with overall survival (Table 3 and Fig. 4 ).
The overexpression of CCR7 predicts lymph node metastases in triple negative breast cancers
In previous studies [3] [4] [5] [6] [7] [8] , the CCR7 expression was shown to be positively correlated with the incidence of lymph node metastases, while its predictive value of prognosis in breast cancer remains contradictory (Table 1) . Having investigated the prognostic relevance of the expression of CCR7, we then turned to assess whether CCR7 expression was associated with the incidence of lymph node metastases. The expression levels of CCR7 showed a positive correlation with the incidence of lymph node metastases (p=0.0096), suggesting that CCR7 positive samples likely had a higher rate of lymph node metastases (Fig. 4A) . These results indicated that triple negative breast cancers overexpressing CCR7 exhibited a better prognosis but showed a higher rate of lymph node metastases. The reason, why triple negative breast cancers expressed CCR7 at high levels and resulted in a better overall prognosis, would be explained in the discussion section. 
Discussion
In the present study, we investigated the expression of CCR7 in various breast cancer subtypes using data from the gene, mRNA, and protein levels. To the best of our knowledge, the current study provides one of the most comprehensive reports on CCR7 expressions in breast cancer in the literature. From the combined results of these analyses, we can draw a unanimous conclusion that CCR7 can serve as a potential prognostic marker, with best predictive value in the triple negative breast cancer subtype.
To address the relationship between CCR7 expression and patient prognosis, we first analyzed CCR7 gene amplification in breast cancer database and found a prognostic correlation. Further analysis with mRNA expression data confirmed such result, which led to a consistent conclusion that the high expression levels of CCR7 mRNA also predict a good prognosis, especially in the basal-like subtype. Importantly, we verified the prognostic significance of CCR7 expression using the results from the immunohistochemical analysis of 188 triple negative breast cancer tissues. Consistent with our observations with data from the gene and mRNA levels, the CCR7 protein positive group also showed a better prognosis. Previous studies [3, 4, 7] have reported a higher rate of lymph node metastases in the CCR7 positive group, and similar results were also reached in this present study ( Table 1) .
The functions of CCR7 involve the regulation of the migration of immune cells to lymph nodes [11, 12] . Such roles have been extensively studied in adaptive immunity and secondary lymphoid organogenesis [13, 14] . The CCR7-null mice mutant displayed a disrupted architecture of the thymus and lymph nodes, as well as reduced primary immune response [9] . Hence, we hypothesize that the expression of CCR7 could increase the migration of breast cancer cells to lymph nodes. However, it remains obscure how the increased migration of breast cancer cells to lymph nodes led to good prognosis. We have considered several possibilities, which are as follows. Firstly, it was unclear what functions CCR7 positive cancer cells in lymph nodes played during the development and progression of cancer. CCR7 positive cancer cells actively directed metastasis to lymph nodes but might also activate the immune system to trap escaped tumor cells [15] . In support of this notion, previous studies have reported that CCR7 actively targeted migration to the lymph nodes, but led to less efficient metastasis to the lung in PyVmT mice models [9] . The correlation between chemokine receptors and lymph node metastases could provide a new understanding of breast cancer metastasis, which is worthy for further studies to develop novel therapies. Secondly, an appropriate mice model is required to understand the development of targeting metastasis from the mammary fat pad to the lymph nodes. Boyle et al [16] . reported that CCR7 was not implicated in enhancing breast tumor growth or regulating breast tumor proliferation in a tissue-specific manner. The CCR7 positive tumors might be more sensitive to chemotherapy, leading to a longer survival time in CCR7 positive patients. However, no such study was carried out yet in this regard, thus in our further studies we will try to address this issue in order to reveal the implications of CCR7 expression. Interestingly, Gracio et al [17] . identified that the CCR7 splicing imbalance was associated with clinical outcomes. Therefore, a close examination of CCR7 alternative splicing in breast cancer should be performed to disclose the associations of this key post-transcriptional regulation with patient survival [18] .
The major limitation of the current study is due to the ret rospective analysis. Meanwhile, the small sample size reduced the statistical power, and the limited number of samples expressing CCR7 should also be considered as a limiting factor in data analysis. In addi tion, the data presented here did not fully address the reason why triple negative breast cancers expressed CCR7 at high levels and resulted in a better overall prognosis. Further studies using cancer cell lines and animal models will be explored to gain more mechanistic insights into the implications of CCR7 expression in disease progression.
